Lung Cancer Trial, Recruiting NCT05838053 Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05838053
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your tumor is 2 cm (about 3/4 of an inch) or smaller
  • You have a single tumor located in the outer part of the lung
  • Scans before surgery showed either one nodule, or any additional nodules were at an early, less aggressive stage
  • During surgery, a tissue sample confirmed a specific type of lung cancer (invasive adenocarcinoma) with certain growth patterns present in more than 5% of the sample
  • Surgery confirmed that the entire tumor was fully removed with clear edges (no cancer cells left behind)
  • Your lung function is strong enough to safely handle either type of surgery being studied (confirm with trial site)
  • Your other organs (such as liver and kidneys) are functioning well enough
  • You are reasonably active and able to care for yourself day-to-day (a score of 0, 1, or 2 on a standard activity scale)
  • You are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • Your tumor is positioned too close to the central part of the lung, making one of the surgical options not possible
  • Tests before surgery suggested cancer may have spread to your lymph nodes
  • There is evidence that the cancer has spread to nearby tissues or other parts of the body
  • During surgery, cancer cells were found to have spread to the lining around the lung
  • You have serious problems with your heart, liver, or kidney function (confirm with trial site)
  • You have or have had another type of cancer at the same time
  • You have previously received chemotherapy, radiation therapy, or targeted drug therapy for this cancer
  • You have had a serious heart condition or heart attack within the past 6 months
  • The research team has determined for other reasons that you are not a suitable candidate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Registry
ClinicalTrials.gov
Start date
20 August 2019
Est. completion
30 April 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

recurrence-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov